Skip Navigation

European Heart Journal 1988 9(2):223-227;
Copyright © 1988 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by FURBERG, C. D.
Right arrow Articles by BLACK, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by FURBERG, C. D.
Right arrow Articles by BLACK, D. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1988 The European Society of Cardiology

The systolic hypertension in the elderly pilot program: Methodological issues*

C. D. FURBERG{dagger}, and D. M. BLACK{ddagger}

{dagger}Bowman Gray School of Medicine Winston-Salem, NC, U.S.A.
{ddagger}Department of Epidemiology and International Health, University of California San Francisco, CA, U.S.A

address for correspondence: Curt D. Furberg, M.D., bowman Gray School of Medicine, Winston-Salem, NC 27103, U.S.A

Abstract

The Systolic Hypertension in the Elderly Program (SHEP) Pilot Study was conducted to determine the feasibility of conducting a long-term placebo-controlled randomized clinical trial in elderly subjects. Enrolled in the study were 551 men and women between the ages of 60 and 90 years with isolated systolic hypertension (SBP ≥ 160 mmHg and DBP < 90 mmHg). The study showed that it is possible to recruit old and very old subjects into a clinical trial; the elderly are good compliers (drugs and follow-up visits), with some decline after the age of 80; control of blood pressure was accomplished in the large majority of patients; evaluation of side effects represents a potential problem as varied complaints increase with age thus creating difficulties in distinguishing those attributed to the study drug; and finally, cause-specific mortality is probably preferable to all-cause mortality as an end-point in prevention trials of antihypertensive regimens.

Key Words: Isolated systolic hypertension • elderly • antihypertensive agents • clinical trial


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 ANN INTERN MEDHome page
W. B. Applegate
Hypertension in Elderly Patients
Ann Intern Med, June 1, 1989; 110(11): 901 - 915.
[Abstract] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.